IL324969A - מקרו-מחזורים לטיפול במחלות אוטואימוניות - Google Patents

מקרו-מחזורים לטיפול במחלות אוטואימוניות

Info

Publication number
IL324969A
IL324969A IL324969A IL32496925A IL324969A IL 324969 A IL324969 A IL 324969A IL 324969 A IL324969 A IL 324969A IL 32496925 A IL32496925 A IL 32496925A IL 324969 A IL324969 A IL 324969A
Authority
IL
Israel
Prior art keywords
6alkyl
pyrimidin
pyrazolo
dimethyl
heptaen
Prior art date
Application number
IL324969A
Other languages
English (en)
Inventor
Buyu Kou
Haixia Liu
Hong Shen
Yao Wu
Zhiwei Zhang
Wei Zhu
Original Assignee
Hoffmann La Roche
Buyu Kou
Haixia Liu
Hong Shen
Yao Wu
Zhiwei Zhang
Wei Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Buyu Kou, Haixia Liu, Hong Shen, Yao Wu, Zhiwei Zhang, Wei Zhu filed Critical Hoffmann La Roche
Publication of IL324969A publication Critical patent/IL324969A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL324969A 2023-07-19 2024-07-17 מקרו-מחזורים לטיפול במחלות אוטואימוניות IL324969A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023108207 2023-07-19
PCT/EP2024/070202 WO2025017045A1 (en) 2023-07-19 2024-07-17 Macrocycles for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
IL324969A true IL324969A (he) 2026-01-01

Family

ID=91966078

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324969A IL324969A (he) 2023-07-19 2024-07-17 מקרו-מחזורים לטיפול במחלות אוטואימוניות

Country Status (13)

Country Link
EP (1) EP4746963A1 (he)
JP (1) JP2026525329A (he)
KR (1) KR20260040007A (he)
CN (1) CN121568945A (he)
AR (1) AR133266A1 (he)
AU (1) AU2024296084A1 (he)
CL (1) CL2026000081A1 (he)
CO (1) CO2026000531A2 (he)
IL (1) IL324969A (he)
MX (1) MX2026000537A (he)
PE (1) PE20260753A1 (he)
TW (1) TW202510858A (he)
WO (1) WO2025017045A1 (he)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
KR20210146370A (ko) * 2019-03-28 2021-12-03 루핀 리미티드 Sting 효능제로서의 매크로사이클릭 화합물
DK4004002T3 (da) * 2019-07-22 2024-09-30 Lupin Ltd Makrocykliske forbindelser som sting-agonister samt fremgangsmåder og anvendelser dermed
IL314136A (he) * 2022-02-02 2024-09-01 Hoffmann La Roche אימידאזול מקרוציקלים לטיפול במחלות אוטואימוניות

Also Published As

Publication number Publication date
AU2024296084A1 (en) 2025-12-11
KR20260040007A (ko) 2026-03-23
CO2026000531A2 (es) 2026-02-02
CN121568945A (zh) 2026-02-24
TW202510858A (zh) 2025-03-16
PE20260753A1 (es) 2026-03-31
AR133266A1 (es) 2025-09-10
CL2026000081A1 (es) 2026-04-06
JP2026525329A (ja) 2026-07-29
EP4746963A1 (en) 2026-05-27
WO2025017045A1 (en) 2025-01-23
MX2026000537A (es) 2026-03-02

Similar Documents

Publication Publication Date Title
US12077536B2 (en) BCL-2 inhibitors
US12398154B2 (en) Azaquinazoline pan-KRas inhibitors
US20260015350A1 (en) Azaquinazoline pan-kras inhibitors
US20250368649A1 (en) Tetrahydropyridopyrimidine pan-kras inhibitors
US20240287101A1 (en) Cereblon-based kras degrading protacs and uses related thereto
IL294048A (he) מעכבי sos1
TW202328124A (zh) 1,4-氧雜氮雜環庚烷衍生物及其用途
WO2025017045A1 (en) Macrocycles for the treatment of autoimmune disease
TW202122396A (zh) KRas G12D抑制劑
EP4472739A1 (en) Imidazole macrocycles for the treatment of autoimmune disease
WO2025012195A1 (en) Bicyclic macrocycles for the treatment of autoimmune disease
US20240366770A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CN110036012A (zh) 吡啶并[3,4-d]嘧啶衍生物及其药学上可接受的盐
CN117980297A (zh) 作为egfr抑制剂的取代的氨基吡啶化合物
EP4739670A1 (en) Macrocycles for the treatment of autoimmune disease
WO2025021666A1 (en) Macrocycles for the treatment of autoimmune disease